Therapeutic potential of CD20 x CD3 bispecific antibodies

FHS
April 5, 2024
5:24 am

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

Large-scale study uncovers modifiable risk factors for young-onset dementia

Researchers have identified a wide range of risk factors for young-onset dementia.

December 27, 2023

Mom’s 911 Call for Her Son’s Mental Health Ends With His Death After Police Response

Taylor Ware’s mom just wanted to get her son the help he needed. But her home was 400 miles away and Ware was deep into

March 29, 2024

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag – Pharmaceutical Technology

Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. Image credit: Sergiy Palamarchuk / Shutterstock. MSD

October 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.